6-(3-(4-(o-methoxyphenyl)-1-piperazinyl)propylamino)-1,3-dimethyluracil
urapidil
CAS: 34661-75-1
Molecular Formula: C20H29N5O3
6-(3-(4-(o-methoxyphenyl)-1-piperazinyl)propylamino)-1,3-dimethyluracil - Names and Identifiers
| Name | urapidil |
| Synonyms | b-66256 ebrantil urapidil URAPIDIL 6-(3-(4-(o-methoxyphenyl)-1-piperazinyl)propylamino)-1,3-dimethyluracil 1,3-dimethyl-6-(3-(4-(o-methoxyphenyl)-1-piperazinyl)proppylamino)-uraci 6-[[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino]-1,3-dimethyluracil 6-[[3-[4-(2-Methoxyphenyl)-1-Piperazinyl]Propyl]Amino]-1,3-Dimethyluracil 6-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propylamino]-1,3-dimethylpyrimidine-2,4-dione 6-[3-[4-(2-methoxyphenyl)-1-piperazinyl]propylamino]-1,3-dimethylpyrimidine-2,4-dione 6-({3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl}amino)-1,3-dimethylpyrimidine-2,4(1H,3H)-dione 6-[[3-[4-(2-methoxyphenyl)-1-piperazinyl]-propyl]amino]1,3-dimethyl-2,4(1H,3H)-pyrimidinedione |
| CAS | 34661-75-1 |
| EINECS | 252-130-4 |
| InChI | InChI=1/C20H29N5O3/c1-22-18(15-19(26)23(2)20(22)27)21-9-6-10-24-11-13-25(14-12-24)16-7-4-5-8-17(16)28-3/h4-5,7-8,15,21H,6,9-14H2,1-3H3 |
6-(3-(4-(o-methoxyphenyl)-1-piperazinyl)propylamino)-1,3-dimethyluracil - Physico-chemical Properties
| Molecular Formula | C20H29N5O3 |
| Molar Mass | 387.48 |
| Density | 1.2058 (rough estimate) |
| Melting Point | 156-158° |
| Boling Point | 513.42°C (rough estimate) |
| Flash Point | 285.8°C |
| Solubility | DMSO: >10mg/mL |
| Vapor Presure | 4.22E-12mmHg at 25°C |
| Appearance | Needle crystal |
| Color | White to Light yellow to Light orange |
| Maximum wavelength(λmax) | ['268nm(MeOH)(lit.)'] |
| Merck | 14,9865 |
| pKa | 7.10(at 25℃) |
| Storage Condition | Sealed in dry,Room Temperature |
| Refractive Index | 1.7600 (estimate) |
| MDL | MFCD00133908 |
| In vitro study | Urapidil is an α1 adrenoreceptor antagonist and a 5-HT 1A receptor agonist. Urapidil does not affect vascular tone at concentrations up to 10 -5 M. Urapidil (10 -5 M) markedly inhibits the alpha 1-adrenergic agonist (phenylephrine)-induced concentration-dependent contractions in aortic rings without endothelium and also to some extent in those with endothelium. Moreover, the inhibitory effect of Urapidil is more pronounced in rings without endothelium than in those with endothelium. Urapidil (10 -5 M) affects neither the vascular tone nor the concentration-dependent contraction to serotonin. |
6-(3-(4-(o-methoxyphenyl)-1-piperazinyl)propylamino)-1,3-dimethyluracil - Risk and Safety
| Hazard Symbols | Xn - Harmful |
| Risk Codes | R22 - Harmful if swallowed R36/37/38 - Irritating to eyes, respiratory system and skin. |
| Safety Description | 26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. |
| RTECS | YQ9862000 |
| Toxicity | LD50 in male mice, rats (mg/kg): 750, 550 orally; 260, 145 i.v. (Koenig) |
6-(3-(4-(o-methoxyphenyl)-1-piperazinyl)propylamino)-1,3-dimethyluracil - Standard
Authoritative Data Verified Data
This product is 6-[[3-[4-(2-methoxyphenyl)-l-farnesyl] propyl] Endo]-1, 3-dimethyluracil. Calculated as the dried product, including not less than 99.0%.
Last Update：2024-01-02 23:10:35
6-(3-(4-(o-methoxyphenyl)-1-piperazinyl)propylamino)-1,3-dimethyluracil - Trait
Authoritative Data Verified Data
- This product is white crystal or crystalline powder; Odorless.
- This product is soluble in chloroform, dissolved in methanol or ethanol, slightly soluble in acetone, insoluble in petroleum ether or water; Slightly soluble in 0.lmol / L hydrochloric acid solution.
Last Update：2022-01-01 11:32:46
6-(3-(4-(o-methoxyphenyl)-1-piperazinyl)propylamino)-1,3-dimethyluracil - Differential diagnosis
Authoritative Data Verified Data
- take about 50mg of this product, add about 30mg of malonic acid and 0.5 of acetic anhydride, and heat in a water bath at 80-90°C for 10 minutes, which should be red-brown.
- This product is dissolved in methanol and diluted to prepare a solution containing 8ug per lml, which is determined by UV-Vis spectrophotometry (General 0401), there is an absorption maximum at a wavelength of 268nm.
- The infrared absorption spectrum of this product should be consistent with that of the control (Spectrum set 910).
Last Update：2022-01-01 11:32:47
6-(3-(4-(o-methoxyphenyl)-1-piperazinyl)propylamino)-1,3-dimethyluracil - Exam
Authoritative Data Verified Data
clarity and color of solution
take this product 0.5g, add 0.lmol/L hydrochloric acid solution 25ml, the solution should be clear and colorless.
Related substances
take an appropriate amount of this product, add the mobile phase to dissolve and dilute to make a solution containing lmg per lml, as a test solution; Take a sample solution of lml with precision, in a 200ml measuring flask, dilute to the scale with mobile phase, and shake well as
Control solution. According to the chromatographic conditions under the content determination item, 20 u1 of the test solution and the control solution are respectively injected into the liquid chromatograph, and the chromatogram is recorded to 2 times of the retention time of the main component peak. If there are impurity peaks in the chromatogram of the test solution, the area of a single impurity peak shall not be greater than the area of the main peak of the control solution (0.5% ), the sum of each impurity peak area shall not be greater than 2 times (1.0%) of the main peak area of the control solution.
residual solvent
take this product about lg, precision weighing, top empty bottle, precision plus dilute sulfuric acid 10ml, sealed, as a test solution; Another precision weighing 1, 2-dichloroethane, the appropriate amount of ethanol, acetone and benzene was added to dilute sulfuric acid to make a solution containing 0.5ug of 1, 2-dichloroethane, 0.5mg of ethanol, mg of acetone and 0.2ug of benzene per 1 ml, 10ml was precisely weighed, placed in a top empty bottle, sealed, and used as a reference solution. According to the determination method of residual solvent (General Principle 0861 first method), the capillary column with polyethylene glycol as stationary liquid is used as the column; The column temperature is 80°C; The detector temperature is 200°C; the inlet temperature was 200°C; The headspace bottle equilibration temperature was 85°C and the equilibration time was 30 minutes. Take the reference solution into the headspace, and the separation degree between the chromatographic peaks of each component shall meet the requirements. The sample solution and the reference solution were sampled by Headspace injection, and the chromatogram was recorded. The peak area was calculated according to the external standard method, 1, 2-dichloroethane, ethanol, the residual amount of acetone and benzene shall be in accordance with the regulations.
loss on drying
take this product, dry to constant weight at 105°C, weight loss shall not exceed 0.5% (General rule 0831).
ignition residue
take l.Og of this product and check it according to law (General rule 0841). The residue left shall not exceed 0.1%.
Heavy metals
The residue left under the item of taking the ignition residue shall not contain more than 20 parts per million of heavy metal when examined by law (General rule 0821, Law II).
Last Update：2022-01-01 11:32:48
6-(3-(4-(o-methoxyphenyl)-1-piperazinyl)propylamino)-1,3-dimethyluracil - Content determination
Authoritative Data Verified Data
measured by high performance liquid chromatography (General 0512).
chromatographic conditions and system suitability test
silica gel bonded with eighteen alkyl silane was used as the filler; Sodium acetate solution (8.2g of anhydrous sodium acetate and 40ml of glacial acetic acid were taken, dissolved in water and diluted to 600ml)-methanol (70:30) was used as the mobile phase; the detection wavelength was 268nm. Urapidil and 1, 3-dimethyl-4-(y-chloropropyl amino) uracil (impurity I), the mobile phase was added and dissolved and diluted to prepare urapidil containing 0.lmg with impurities 10.20M1 of the mixed solution of Olmg is injected into the liquid chromatograph, and the chromatogram is recorded. The separation degree of urapidil peak and impurity I peak shall meet the requirements, and the number of theoretical plates shall not be less than 2000 based on urapidil.
assay
take about 25mg of this product, precision weighing, put in 25ml measuring flask, add mobile phase to dissolve and dilute to the scale, shake, take 5ml precision, put in 50ml measuring flask, dilute to scale with mobile phase, shake well, take 20ul with precision, inject into liquid chromatograph, record chromatogram; Take appropriate amount of urapidil reference, the mobile phase was added for dissolution and quantitative dilution to make about 0.lmg solution, the same method for determination. According to the external standard method to calculate the peak area, that is.
Last Update：2022-01-01 11:32:48
6-(3-(4-(o-methoxyphenyl)-1-piperazinyl)propylamino)-1,3-dimethyluracil - Category
Authoritative Data Verified Data
antihypertensive drugs.
Last Update：2022-01-01 11:32:48
6-(3-(4-(o-methoxyphenyl)-1-piperazinyl)propylamino)-1,3-dimethyluracil - Storage
Authoritative Data Verified Data
shade, seal, and store in a cool place.
Last Update：2022-01-01 11:32:49
6-(3-(4-(o-methoxyphenyl)-1-piperazinyl)propylamino)-1,3-dimethyluracil - Urapidil injection
Authoritative Data Verified Data
This product is a sterile aqueous solution of urapidil. Containing urapidil (C20H9N602) shall be between 95.0% and 105.0% of the labeled amount.
trait
This product is colorless or almost colorless clear liquid.
identification
- take an appropriate amount of this product and dilute it with water to make urapidil in about 0. A solution of Olmg has an absorption maximum at a wavelength of 0401 nm as determined by UV-Vis spectrophotometry (general).
- in the chromatogram recorded under the content determination item, the retention time of the main peak of the test solution should be consistent with the retention time of the main peak of the reference solution.
examination
- the pH value should be 4.0 to 7.0 (General 0631).
- Related substances take 5ml of this product, put it in a 25ml measuring flask, dilute it to the scale with mobile phase, shake it, and use it as a test solution. Take 1ml for precision measurement and put it in a 200ml measuring flask, dilute to the scale with the mobile phase, shake, and serve as a control solution. According to the chromatographic conditions under the content determination item, 20 u1 of the test solution and the control solution are respectively injected into the liquid chromatograph, and the chromatogram is recorded to 2 times of the retention time of the main component peak. If there are impurity peaks in the chromatogram of the test solution, the area of a single impurity peak shall not be greater than the area of the main peak of the control solution (0.5% ), the sum of each impurity peak area shall not be greater than 2 times (1.0%) of the main peak area of the control solution.
- the bacterial endotoxin of this product is taken and checked according to law (General rule 1143). The amount of endotoxin contained in urapidil should be less than 1.0EU per 1 mg.
- others should comply with the relevant provisions under injection (General 0102).
Content determination
- measured by high performance liquid chromatography (General 0512).
- chromatographic conditions and system suitability test using eighteen alkyl silane bonded silica gel as filler; Sodium acetate solution (take anhydrous sodium acetate 8.2g and glacial acetic acid 40ml, add water to dissolve and dilute to 600ml)-Methanol (70:30) as mobile phase; Column temperature was 30°C; Detection wavelength was 268nm. Appropriate amounts of urapidil control and impurity I control were taken, dissolved and diluted with mobile phase to make urapidil 0.lmg with impurities 1O. The mixed solution of Olmg is injected with 20u1 into the liquid chromatograph, and the chromatogram is recorded. The separation degree of urapidil peak and impurity I peak shall meet the requirements, and the number of theoretical plates shall not be less than 2000 based on urapidil peak.
- precision measurement 2ml of this product was placed in a 100ml measuring flask, diluted to the scale with mobile phase, and then shaken to be used as a test solution, put it in a 25ml measuring flask, add the mobile phase to dissolve and dilute to the scale, shake well, then take 5ml accurately, put it in a 50ml measuring flask, dilute it to the scale with the mobile phase, shake well, and use it as a reference solution. 20 u1 of the test solution and the reference solution were respectively injected into the liquid chromatograph, and the chromatogram was recorded. The peak area was calculated according to the external standard method.
category
Same as urapidil.
specification
5ml : 25mg
storage
shade, close, and store in a cool place.
Last Update：2022-01-01 11:32:50
6-(3-(4-(o-methoxyphenyl)-1-piperazinyl)propylamino)-1,3-dimethyluracil - Reference Information
| adverse reactions taboo | after URA is used, there may be some transient hypotension reactions, such as headache, dizziness, nausea, etc., with low incidence, tolerance of patients and no serious adverse reactions. Patients with aortic stenosis or arteriovenous shunts (except for hemodynamically ineffective dialysis shunts) are contraindicated. It is forbidden for lactating women. |
| clinical application | 1. all kinds of hypertension (1) essential hypertension URA has significant antihypertensive effect on essential hypertension, and URA has more obvious effect on systolic blood pressure reduction, minimal effect on heart rate, low incidence of adverse reactions, and patient tolerance. (2) severe hypertension after using URA, SBP, DBP and HR were significantly reduced compared with those before medication. And with the extension of medication time, the more obvious the antihypertensive effect is, and it does not cause reflex tachycardia. Compared with antihypertensive drugs such as sodium nitroprusside, nitroglycerin and phentolamine, this is the biggest advantage of URA. (3) hypertension emergency URA has a fast antihypertensive effect and is effective for hypertension caused by various reasons. The symptoms of patients in URA group improved well, and there were no orthostatic hypotension, flushing, palpitations and other side effects in phentolamine group. (4) Pulmonary hypertension α1 receptor widely exists in the pulmonary vascular bed. URA blocks α1 receptor, reduces pulmonary artery pressure, avoids vasodilation in hypoxic area, and does not aggravate functional arteriovenous shunt, so as to maintain or increase arterial partial pressure. The results showed that the total effective rate of URA in the treatment of pulmonary hypertension, heart failure and pulmonary heart disease was 91.66%,P(O2) increased 25.31%, the average pulmonary artery pressure and pulmonary hair incarceration pressure decreased significantly, and decreased 28.74% and 35.62% respectively. At the same time, the product of systolic blood pressure and heart rate is also reduced, reflecting the reduction of myocardial oxygen consumption, which is beneficial to myocardial protection. 2. all kinds of heart failure (1) acute left heart failure URA 25 mg plus normal saline 10 mL,iv,5min. URA 112.5 mg plus 5% glucose 500 mL for intravenous drip. Results URA can significantly reduce SBP,DBP and HR and the product of SBP and HR in patients with acute left heart failure. Blood pressure decreased significantly at 5~15 min after administration, and dropped to the lowest point at 60 min. Compared with SBP and DBP before administration, they decreased by 26.8% and 24.6% respectively, and left ventricular systolic function was significantly improved. It has been reported that URA is significantly better than nitroglycerin in the treatment of acute left heart failure. In 69 patients, the total effective rate of URA is 97% and nitroglycerin is 80%. And URA has little side effect. (2) congestive heart failure (CHF) URA12.5~25 mg + normal saline 20 mL,iv,3~5 min, followed by 50~100 mg URA + 5% glucose 250~500 mL intravenous drip. Results The effective rate of URA in improving cardiac function in patients with congestive heart failure was 92%, and the clinical symptoms were significantly improved. At the same time, URA directly dilated renal vessels, increased renal vascular perfusion, and improved renal function, thus reducing blood and urine β2-MG after heart failure correction. |
| Biological activity | Urapidil is an antagonist of α1 adrenoceptor and an agonist of 5-HT1A receptor. |
Last Update：2024-04-09 19:05:11
Supplier List
Product Name: urapidil Request for quotation
CAS: 34661-75-1
Tel: 0086-551-65418684
Email: sales@tnjchem.com
info@tnjchem.com
Mobile: 0086 189 4982 3763
QQ: 2881500840
Wechat: 0086 189 4982 3763
WhatsApp: 0086 189 4982 3763
Product List: View Catalog
CAS: 34661-75-1
Tel: 0086-551-65418684
Email: sales@tnjchem.com
info@tnjchem.com
Mobile: 0086 189 4982 3763
QQ: 2881500840
Wechat: 0086 189 4982 3763
WhatsApp: 0086 189 4982 3763
Product List: View Catalog
Spot supply
Product Name: Urapidil Visit Supplier Webpage Request for quotationCAS: 34661-75-1
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Product Name: urapidil Request for quotation
CAS: 34661-75-1
Tel: 0086-551-65418684
Email: sales@tnjchem.com
info@tnjchem.com
Mobile: 0086 189 4982 3763
QQ: 2881500840
Wechat: 0086 189 4982 3763
WhatsApp: 0086 189 4982 3763
Product List: View Catalog
CAS: 34661-75-1
Tel: 0086-551-65418684
Email: sales@tnjchem.com
info@tnjchem.com
Mobile: 0086 189 4982 3763
QQ: 2881500840
Wechat: 0086 189 4982 3763
WhatsApp: 0086 189 4982 3763
Product List: View Catalog
Spot supply
Product Name: Urapidil Visit Supplier Webpage Request for quotationCAS: 34661-75-1
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History